(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
In Molecular Diagnostics for Melanoma: Methods and Protocols, expert researchers and clinicians in the field of melanoma provide updated information on biomarkers and assays for diagnosis, prognosis, and assays predicting response to treatment for routine testing. The focus of the volume is on biomarkers with established clinical validity rather than those on early discovery stage. With additional in-depth discussion of the molecular biology and pathology of melanoma, treatment options in adjuvant and metastatic setting, and implications of biomarker testing for clinical management of melanoma patients.
Written in the highly successful Methods in Molecular Biology series format, chapters include extensive introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and key tips on troubleshooting and avoiding known pitfalls.
Comprehensive and practical, Molecular Diagnostics for Melanoma: Methods and Protocols seeks to provide both clinicians and scientists with technical information and extensive background information on the wide ranging approaches available in the field of diagnostics of melanoma.
Contents:
Part I. Clinical Challenges and Current Status of Treatment of Melanoma
1. Novel Insights/translational Implication from the Emerging Biology of Melanoma
Antoni Ribas
2. Emerging Clinical Issues in Melanoma in the Molecularly Targeted Era
Ryan J. Sullivan and Michael B. Atkins
3. Integrating Molecular Biomarkers Into Current Clinical Management In Melanoma
Ragini Kudchadkar, Geoffrey Gibney, and Vernon K. Sondak
Part II. Biomarkers for Prediction of Response and Resistance to Treatment
4. Advances in Adjuvant Therapy: Potential for Prognostic and Predictive Biomarkers
Diwakar Davar, Ahmad A. Tarhini, Helen Gogas, and John M. Kirkwood
5. Immunologic Monitoring of Cancer Vaccine Trials Using the ELISPOT Assay
Lisa H. Butterfield and Mary Jo Buffo
6. Markers for Anti-Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) Therapy in Melanoma
Michael A. Postow, Jianda Yuan, Shigehisa Kitano, Alexander M. Lesokhin, and Jedd D. Wolchok
7. Marker Utility for Combination Therapy
Ester Simeone, Antonio M. Grimaldi, and Paolo A. Ascierto
8. Assaying for BRAF V600E in Tissue and Blood in Melanoma
David J. Panka, James W. Mier, and Ryan J. Sullivan
9. Selecting Patients for KIT Inhibition in Melanoma
Richard D. Carvajal, Omid Hamid, and Cristina R. Antonescu
10. Detecting Mechanisms of Acquired BRAF inhibitor Resistance in Melanoma
Roger Lo and Hubing Shi
11. Current Status of Diagnostic and Prognostic Markers in Melanoma
Danielle Levine and David E. Fisher
12. Chromosomal Copy Number Analysis in Melanoma Diagnostics
Jeffrey P. North, Swapna Vemula, and Boris C. Bastian
13. Construction and Analysis of Multi-Parameter Prognostic Models for Melanoma Outcome
Bonnie E. Gould Rothberg and David L. Rimm
14. Immunohistochemical Diagnostic and Prognostic Markers for Melanoma
Mehdi Nosrati and Mohammed Kashani-Sabet
15. Lymphatic Invasion as a Prognostic Biomarker in Primary Cutaneous Melanoma
Xiaowei Xu, Phyllis A. Gimotty, DuPont Guerry, Giorgos Karakousis, and David E. Elder
16. Tumor Infiltrating Lymphocytes and Their Significance in Melanoma Prognosis
Tobias Schatton, Richard A. Scolyer, John F. Thompson, and Martin C. Mihm, Jr.
17. Pathological Staging of Melanoma
David E. Elder
18. Genotyping of Human Leukocyte Antigen (HLA) Ancestral Haplotypes as Prognostic Marker in Cancer Using PCR Analysis
Lisa Villabona, Emilia Andersson, Maddalena Marchesi, and Giuseppe V. Masucci
19. B7-H Abnormalities in Melanoma and Clinical Relevance
Barbara Seliger
20. Melanoma Susceptibility Genes and Risk Assessment
Alexander Marxuka-Alcala, Michele Jacobs Gabree, and Hensin Tsao
Part IV. Uveal Melanoma
21. Clinical, Pathologic, and Imaging Features, and Biological Markers of Uveal Melanoma
Hans E. Grossniklaus and Alia B. Rashid
22. A Prognostic Test to Predict Risk of Metastasis in Uveal Melanoma Based on a 15-Gene Expression Profile
J. William Harbour
23. Molecular Karyotyping for Detection of Prognostic Markers in Fine Needle Aspirate Biopsy Samples of Uveal Melanoma
Arupa Ganguly, Jennifer Richards-Yutz, and Kathryn G. Ewens
Part V. Emerging Markers/Targets in Melanoma
24. ERBB4 Mutation Analysis: Emerging Molecular Target for Melanoma Treatment
Christopher Lau, Keith J. Killian, Yardena Samuels, and Udo Rudloff
25. Epigenetic Markers of Prognosis in Melanoma
Luca Sigalotti, Elisabetta Fratta, Giulia Parisi, Sandra Coral, and Michele Maio
26. Isolation of Melanoma Cell Subpopulations Using Negative Selection
Ana Slipicevic, Rajasekharan Somasundaram, Katrin Sproesser, and Meenhard Herlyn
27. Circulating Tumor Cells as Prognostic Biomarkers in Cutaneous Melanoma Patients
Eiji Kiyohara, Keisuke Hata, Stella Lam, and Dave S. B. Hoon
28. Detection of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Melanoma
Yangyang Wang, Francesco Sabbatino, Xinhui Wang, and Soldano Ferrone
29. Targeting Damage Associated Molecular Pattern Molecules (DAMPs) and DAMP Receptors in Melanoma
Brian A. Boone and Michael T. Lotze
30. The Clinical Use of PET/CT in the Evaluation of Melanoma
Khun Visith Keu and Andrei H. Iagaru
Part VI. Emerging Technologies for Marker Validation
31. Immune System Functional Pathway Analysis Using Single Cell Network Profiling (SCNP): A Novel Tool in Cancer Immunotherapy
Alessandra Cesano
32. Quantitative and Spatial Image Analysis of Tumor and Draining Lymph Nodes Using Immunohistochemistry and High Resolution Multispectral Imaging to Predict Metastasis
Kim R.M. Blenman and Peter P. Lee
33. COLD-PCR Enriches Low-Level Variant DNA Sequences and Increases the Sensitivity of Genetic Testing
Elena Castellanos-Rizaldos, Coren A. Milbury, Minakshi Guha, and G. Mike Makrigiorgos
34. Isolation of Circulating MicroRNAs from Microvesicles found in Human Plasma
John F. Quackenbush, Pamela B. Cassidy, Lawrence M. Pfeffer, Kenneth M. Boucher, Jason E. Hawkes, Susan R. Pfeffer, Levy Kopelovich, and Sancy A. Leachman
35. Detection of Circulating Tumor Cells by Photoacustic Flowmetry
Ryan M. Weight and James A. Viator
Part VII. Marker Validation Requirements for Clinical Applicability
36. Statistical Design and Evaluation of Biomarker Studies
Kevin K. Dobbin
37. Tissue Resources for Clinical Use and Marker Studies in Melanoma
Jonathan L. Curry, Michael A. Davies, Tiffany L. Calderone, Katherine Nathanson, Victor G. Prieto, and Jeffrey Gershenwald.
PRODUCT DETAILS
Publisher: Springer (Humana Press Inc.)
Publication date: November, 2013
Pages: 707
Weight: 652g
Availability: Available
Subcategories: Oncology
From the same series
